Redwire Corporation Secures $25 Million NASA Contract for Biotechnology Support on ISS

Reuters
08/28
Redwire Corporation Secures $25 Million NASA Contract for Biotechnology Support on ISS

Redwire Corporation has been awarded a NASA single award, indefinite-delivery/indefinite-quantity (IDIQ) contract with a ceiling of $25 million over a five-year period. This contract enables Redwire to fulfill future task orders for biotechnology facilities, on-orbit operations support, mission integration, and related services aboard the International Space Station (ISS). Recently, a $2.5 million task order was issued to Redwire under NASA's In Space Production Applications (InSPA) program to aid in drug development investigations using Redwire's PIL-BOX technology. As a global leader in microgravity research and development technologies, Redwire is set to manage and facilitate experiments and support on-orbit operations for NASA-funded research. The company's biotechnology facilities play a crucial role in NASA's ISS research strategy, expanding on-orbit capabilities in fields such as drug development, cancer research, and tissue engineering.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redwire Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250828913799) on August 28, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10